SciClone Pharmaceuticals (Holdings) (HKSE:06600) Book Value per Share : HK$5.70 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Book Value per Share?

SciClone Pharmaceuticals (Holdings)'s book value per share for the quarter that ended in Dec. 2023 was HK$5.70.

During the past 12 months, SciClone Pharmaceuticals (Holdings)'s average Book Value Per Share Growth Rate was 18.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 118.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 32.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of SciClone Pharmaceuticals (Holdings) was 118.60% per year. The lowest was -31.30% per year. And the median was 28.95% per year.

SciClone Pharmaceuticals (Holdings)'s current price is HK$18.64. Its book value per share for the quarter that ended in Dec. 2023 was HK$5.70. Hence, today's PB Ratio of SciClone Pharmaceuticals (Holdings) is 3.27.

During the past 7 years, the highest P/B Ratio of SciClone Pharmaceuticals (Holdings) was 32.26. The lowest was 1.36. And the median was 2.17.

SciClone Pharmaceuticals (Holdings) Book Value per Share Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Book Value per Share Chart

SciClone Pharmaceuticals (Holdings) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Book Value per Share

Get a 7-Day Free Trial

2.50

0.55

4.17

4.81

5.70

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Book Value per Share	Get a 7-Day Free Trial						4.17	4.50	4.81	4.98	5.70

Competitive Comparison of SciClone Pharmaceuticals (Holdings)'s Book Value per Share

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals (Holdings)'s PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SciClone Pharmaceuticals (Holdings)'s PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals (Holdings)'s PB Ratio distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals (Holdings)'s PB Ratio falls into.

SciClone Pharmaceuticals (Holdings) Book Value per Share Calculation

SciClone Pharmaceuticals (Holdings)'s Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3,571	-	0)	/	627
	=	5.70

SciClone Pharmaceuticals (Holdings)'s Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3,571	-	0)	/	627
	=	5.70

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

SciClone Pharmaceuticals (Holdings) Book Value per Share Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Book Value per Share

Traded in Other Exchanges

N/A

Address

381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN

Website

https://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Zhao Hong	2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang	2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited	2501 Other
Ascendent Capital Partners Ii Gp Limited	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p.	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p.	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited	2101 Beneficial owner
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Bank Of China Limited	2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited	2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines